Markets Gone Wild

Moleculin Biotech Announces First Country Regulatory Approval in Europe for Phase 3 Trial of Annamycin and Cytarabine Combination for Refractory/Relapsed Acute Myeloid Leukemia Moleculin Biotech, Inc., a biopharmaceutical company specializing in the development of drugs for hard-to-treat tumors and viruses, recently announced its first regulatory approval for its Phase 3 pivotal trial of Annamycin in…

Cornerstone Strategic Investment Fund and Cornerstone Total Return Fund Announce Monthly Distributions New York, Feb. 07, 2025 (GLOBE NEWSWIRE) Cornerstone Strategic Investment Fund, Inc. (NYSE American: CLM) (CUSIP: 21924B302) and Cornerstone Total Return Fund, Inc. (NYSE American: CRF) (CUSIP: 21924U300), each a closed-end management investment company, have announced their monthly distributions. As part of their…

Understanding the Cardlytics, Inc. (CDLX) Lawsuit: What It Means for Investors and the World On March 5, 2025, a notice was issued by ACCESS Newswire regarding a potential recovery for investors who suffered losses from their Cardlytics, Inc. (NASDAQ: CDLX) investments. The notice directed interested parties to follow a link or contact Joseph E. Levi,…

Tempus AI Inc.: A Game-Changer in Healthcare with AI The healthcare industry is on the brink of a technological revolution, and Tempus AI Inc. (TEM) is leading the charge. On Tuesday, shares of this innovative company surged an impressive 35%, bringing its market capitalization to a staggering $7.5 billion. This significant increase was driven by…

Turmalina Metals Corp. Renamed as King Copper Discovery Corp.: A New Era in Mining VANCOUVER, British Columbia, March 04, 2025 – Turmalina Metals Corp. (the “Company” or “Turmalina”), a leading mining company, is thrilled to announce significant changes in its corporate identity. Effective March 11, 2025, the Company will officially be known as “King Copper…

Class Action Lawsuit Filed Against GSK plc: What Does It Mean for Investors and the World? On March 1, 2025, The Schall Law Firm announced that it had filed a class action lawsuit against GSK plc (NYSE:GSK) for alleged securities law violations. The lawsuit, which was filed in the Southern District of New York, accuses…

Rosen Law Firm Announces Filing of Class Action Lawsuit Against Intellia Therapeutics, Inc. On February 18, 2025, Rosen Law Firm, a prominent investor rights law firm based in New York City, announced that a shareholder had filed a class action lawsuit against Intellia Therapeutics, Inc. (NASDAQ: NTLA) on behalf of all persons who purchased securities…